ArticleJCO global oncology2021
Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country.
Article in JCO global oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk Factors for Survival in Patients With Medulloblastoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Long-term outcomes of pediatric medulloblastoma before routine molecular classification: a 20-year single-center cohort study.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- AOSNP-ADAPTR resource level-based recommendations on practical diagnostic strategies for medulloblastomas and other embryonal tumors.Brain pathology (Zurich, Switzerland) · 2026Article
- In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients.Scientific reports · 2025Article
- Strategies for the Molecular Classification of Medulloblastoma.Biomedicines · 2025Review
- Nanopore Sequencing Reveals Novel Alternative Splice Variants of EZH2 in Pediatric Medulloblastoma.Biomedicines · 2025Article
- Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy.Cancer research · 2025Article
- Epidemiology and Outcome of Primary Central Nervous System Tumors Treated at King Hussein Cancer Center.Cancers · 2025Article
- Advancing presurgical non-invasive molecular subgroup prediction in medulloblastoma using artificial intelligence and MRI signatures.Cancer cell · 2024Article
- Case report: Turcot syndrome type 2 in a developing country within the Caribbean.Frontiers in oncology · 2024Article
- Successful Implementation of Image-Guided Pencil-Beam Scanning Proton Therapy in Medulloblastomas.Diagnostics (Basel, Switzerland) · 2023Article
- Efficacy of intrathecal methotrexate in children with high-risk medulloblastoma over three years: a retrospective study from a single center.Journal of neuro-oncology · 2023Article
- Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.Acta neuropathologica · 2023Article
- Prognostic significance of molecular subgroups in survival outcome for children with medulloblastoma in Malaysia.Frontiers in oncology · 2023Article
- How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries?JCO global oncology · 2022Review
- Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression.Acta neuropathologica · 2022Article
- Neurosurgery for Optic Pathway Glioma: Optimizing Multidisciplinary Management.Frontiers in surgery · 2022Review
- Effects of metformin on Sonic hedgehog subgroup medulloblastoma progression:Frontiers in pharmacology · 2022Article
- Outcomes of pediatric medulloblastoma in low- and middle-income countries: A retrospective analysis of 335 cases from 8 countries.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMedulloblastoma is composed of four clinically and prognostically distinct molecular subgroups (WNT, SHH, group 3, and group 4). However, the clinical implications of these subgroups in the context of the unique challenges of low- to middle-income countries are rarely reported.
methodsWe assembled an institutional cohort of children (3-18 years) diagnosed with medulloblastoma and treated in Jordan between 2003 and 2016. Tumors were subgrouped by NanoString and correlated with clinical and radiologic characteristics.
resultsEighty-eight patients were identified (63% male); median age was 6.9 years (interquartile range 4.8-9.2) and median symptom duration was 6 weeks (interquartile range 4-11). Radiotherapy was implemented as standard-risk in 41 patients (47%) and high-risk in 47 patients (53%). Subgrouping revealed 17 WNT (19%), 22 SHH (25%), 21 group 3 (24%), and 28 group 4 tumors (32%). Median time between craniotomy and radiotherapy was 45 days (17-155); 44% of them > 49 days. Median duration of radiotherapy was 44 days (36-74). Seventy-two patients (82%) received chemotherapy afterward. With a median follow-up of 4.6 years (0.2-14.9), 5-year progression-free survival (PFS) and overall survival were 73.5% and 69.4%, respectively, with no statistically significant survival difference between standard-risk and high-risk patients. Metastasis was significant for overall survival (
conclusionPatients with SHH and group 4 medulloblastoma had excellent survival comparable with high-income countries. Compliance with treatment protocols and avoiding radiotherapy delays are important in achieving adequate survival in low- to middle-income country settings. Subgroup-driven treatment protocols should be considered in countries with limited resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.